Masitinib specifically targets mast cells and microglia activity in the neuroimmune system, and may improve AD symptoms by preventing the cell cycle re-entry, improving neuronal plasticity, inhibiting tau phosphorylation, and modulating NMDA receptors by blocking Fyn kinase activity and activation of mast cells and microglia.609 In non-neuronal cells, nilotinib treatment also effectively stimulates the activation of microglia and the proliferation of astrocytes, promotes Aβ clearance, and modulates immune responses in early-stage AD.610. This evidence concerns the gene MAPT and Alzheimer disease.